» Articles » PMID: 27603384

Increased Risk of Cognitive Impairment in Patients with Components of Metabolic Syndrome

Overview
Specialty General Medicine
Date 2016 Sep 8
PMID 27603384
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The number of old adults with cognitive impairment or dementia is anticipated to increase rapidly due to the aging population, especially the number of patients with multiple chronic conditions or metabolic perturbation. Metabolic syndrome (Mets) is among the most hazardous risk factors for cardiovascular disease and is linked to a chronic inflammatory disease. We investigated the National Health and Nutrition Examination Survey (NHANES) database for the years 1999 to 2002 to explore the connection between Mets and cognitive decline.A total of 2252 NHANES (1999-2002)-registered individuals who were stroke-free and aged ≧60 years were enrolled in this study. This study surveyed the effects of the existence of diverse characteristics of Mets on the individuals' cognitive performances as measured with the digit symbol substitution test (DSST).The individuals with more features of Mets achieved lower DSST scores than those with fewer constituents of Mets (P < 0.001 for the trend) after adjustments for covariates. The β coefficients for the DSST scores of the participants with 1, 2, 3, and ≥4 features of Mets were -1.545, -3.866, -4.763, and -5.263, respectively. Cognitive decline was correlated with each of the constituents of Mets, which included high plasma glucose, elevated blood pressure, abdominal obesity, and decreased high-density lipoprotein cholesterol (P < 0.05 for the above factors), with the exception of high triglyceride levels (P > 0.05).Mets was positively associated with cognitive decline in individuals aged ≧60 years. The characteristics of Mets that were most strongly associated with cognitive decline were high plasma glucose and elevated blood pressure.

Citing Articles

Exploring nutraceutical approaches linking metabolic syndrome and cognitive impairment.

Sonnino R, Ciccarelli G, Moffa S, Soldovieri L, Giuseppe G, Brunetti M iScience. 2025; 28(2):111848.

PMID: 40008362 PMC: 11850164. DOI: 10.1016/j.isci.2025.111848.


Metabolic Syndrome Causing Cognitive Impairment in Patients With Schizophrenia: A Systematic Review.

Saxena A, Patel D, Ayesha I, Monson N, Klair N, Patel U Cureus. 2023; 15(10):e47587.

PMID: 38022013 PMC: 10679844. DOI: 10.7759/cureus.47587.


Metabolic syndrome and cognitive deficits in the Greek cohort of Epirus Health Study.

Koutsonida M, Koskeridis F, Markozannes G, Kanellopoulou A, Mousas A, Ntotsikas E Neurol Sci. 2023; 44(10):3523-3533.

PMID: 37162663 PMC: 10495510. DOI: 10.1007/s10072-023-06835-4.


Metabolic profile in first episode drug naïve patients with psychosis and its relation to cognitive functions and social cognition: a case control study.

Sayed S, Gomaa S, Alhazmi A, ElKalla I, Khalil D Sci Rep. 2023; 13(1):5435.

PMID: 37012300 PMC: 10070352. DOI: 10.1038/s41598-023-31829-9.


Identification of a Link between Suspected Metabolic Syndrome and Cognitive Impairment within Pharmaceutical Care in Adults over 75 Years of Age.

Macekova Z, Fazekas T, Krivosova M, Dragasek J, Zufkova V, Klimas J Healthcare (Basel). 2023; 11(5).

PMID: 36900723 PMC: 10000537. DOI: 10.3390/healthcare11050718.


References
1.
Tchistiakova E, Anderson N, Greenwood C, MacIntosh B . Combined effects of type 2 diabetes and hypertension associated with cortical thinning and impaired cerebrovascular reactivity relative to hypertension alone in older adults. Neuroimage Clin. 2014; 5:36-41. PMC: 4066185. DOI: 10.1016/j.nicl.2014.05.020. View

2.
Moloney A, Griffin R, Timmons S, OConnor R, Ravid R, ONeill C . Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2008; 31(2):224-43. DOI: 10.1016/j.neurobiolaging.2008.04.002. View

3.
de Groot J, de Leeuw F, Oudkerk M, van Gijn J, Hofman A, Jolles J . Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000; 47(2):145-51. DOI: 10.1002/1531-8249(200002)47:2<145::aid-ana3>3.3.co;2-g. View

4.
Dahl A, Hassing L, Fransson E, Gatz M, Reynolds C, Pedersen N . Body mass index across midlife and cognitive change in late life. Int J Obes (Lond). 2012; 37(2):296-302. PMC: 3387354. DOI: 10.1038/ijo.2012.37. View

5.
Knopman D, Boland L, Mosley T, Howard G, Liao D, Szklo M . Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001; 56(1):42-8. DOI: 10.1212/wnl.56.1.42. View